Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...
Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback